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Abstract 
Background: Long-lasting, insecticidal nets (LLINs) and indoor residual spraying (IRS) are the most widely accepted 
and applied malaria vector control methods. However, evidence that incremental impact is achieved when they are 
combined remains limited and inconsistent.
Methods: Fourteen population clusters of approximately 1000 residents each in Zambia’s Luangwa and Nyimba 
districts, which had high pre-existing usage rates (81.7 %) of pyrethroid-impregnated LLINs were quasi-randomly 
assigned to receive IRS with either of two pyrethroids, namely deltamethrin [Wetable granules (WG)] and lambdacy-
halothrin [capsule suspension (CS)], with an emulsifiable concentrate (EC) or CS formulation of the organophosphate 
pirimiphos methyl (PM), or with no supplementary vector control measure. Diagnostic positivity of patients tested 
for malaria by community health workers in these clusters was surveyed longitudinally over pre- and post-treatment 
periods spanning 29 months, over which the treatments were allocated and re-allocated in advance of three sequen-
tial rainy seasons.
Results: Supplementation of LLINs with PM CS offered the greatest initial level of protection against malaria in the 
first 3 months of application (incremental protective efficacy (IPE) [95 % confidence interval (CI)] = 0.63 [CI 0.57, 0.69], 
P < 0.001), followed by lambdacyhalothrin (IPE [95 % CI] = 0.31 [0.10, 0.47], P = 0.006) and PM EC (IPE, 0.23 [CI 0.15, 
0.31], P < 0.001) and then by deltamethrin (IPE [95 % CI] = 0.19 [−0.01, 0.35], P = 0.064). Neither pyrethroid formula-
tion provided protection beyond 3 months after spraying, but the protection provided by both PM formulations 
persisted undiminished for longer periods: 6 months for CS and 12 months for EC. The CS formulation of PM provided 
greater protection than the combined pyrethroid IRS formulations throughout its effective life IPE [95 % CI] = 0.79 
[0.75, 0.83] over 6 months. The EC formulation of PM provided incremental protection for the first 3 months (IPE [95 % 
CI] = 0.23 [0.15, 0.31]) that was approximately equivalent to the two pyrethroid formulations (lambdacyhalothrin, IPE 
[95 % CI] = 0.31 [0.10, 0.47] and deltamethrin, IPE [95 % CI] = 0.19 [−0.01, 0.35]) but the additional protection pro-
vided by the former, apparently lasted an entire year.
© 2016 Hamainza et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Open Access
Malaria Journal
*Correspondence:  bossbusk@gmail.com 
1 National Malaria Control Centre, Ministry of Health, Chainama Hospital, 
College Grounds, off Great East road, PO Box 32509, Lusaka, Zambia
Full list of author information is available at the end of the article
Page 2 of 20Hamainza et al. Malar J  (2016) 15:100 
Background
Long-lasting insecticidal nets (LLINs) and indoor resid-
ual spraying (IRS) are the two first-choice malaria vector 
control methods available globally [1] because they can 
achieve massive community-wide impact upon malaria 
transmission, even at partial coverage [2]. This is possible 
because many of the world’s most potent vector species 
prefer people as a source of blood and must feed several 
times upon humans inside houses before they are old 
enough for infectious sporozoite-stage malaria parasites 
to have fully developed within them [3]. While IRS and 
LLINs decrease exposure of directly protected humans to 
infected vectors and vice versa, through contact irritancy 
or spatial repellency, most of the impact of LLINs and 
IRS upon human transmission exposure and parasitae-
mia results from community-level suppression of vector 
population density and infection prevalence, achieved by 
reducing their longevity through lethal exposure to their 
toxic active ingredients [4–6]. The success of these modes 
of action are influenced by the choice, dosage and formu-
lation of insecticide utilized, as well as its coverage and 
mode of application, combined with the behavioural and 
physiological susceptibility of the targeted vector species 
[7–9].
Compared to IRS, LLINs coverage is much higher in 
most endemic countries [10, 11] due to their flexibility of 
delivery mechanism and cheaper costs of implementation 
[12]. Also, while most African vector populations pre-
dominantly feed indoors, at night [13], they may not rest 
on the walls after a blood meal or rest for a period insuf-
ficient to pick up a lethal dose of the active insecticide 
[14]. However, for LLINs to be fully effective they require 
deliberate active participation of individuals to use them 
consistently and appropriately, in addition to them being 
regularly replaced and kept in good repair [15, 16]. In 
contrast, IRS requires only initial consent by the com-
munity to have their houses sprayed and compliance 
with not painting or plastering over the sprayed walls for 
the expected duration of efficacy of the insecticide used. 
Additionally, a major advantage of IRS over LLINs is sim-
ply that the treated surfaces are rarely in direct contact 
with occupants of protected houses so the safety require-
ments for active ingredients that may be used are far less 
stringent and a much wider variety of active ingredients 
can therefore be used [16]. The evidence on the effects 
of combining IRS and LLINs varies, with some studies 
suggesting an incremental benefit of using both interven-
tions [6, 17, 18], while others suggest that IRS adds no 
incremental impact relative to LLINs alone and/or vice 
versa [19–21], that LLINs alone have greater impact than 
IRS [22, 23] and others again indicate that the contrary 
is true [24, 25]. These diverse comparisons between IRS 
and LLINs are based on a variety of outcome measures 
which include impacts on vector densities or entomologi-
cal inoculation rates, including prevalence, incidence or 
diagnostic positivity of parasitaemia among humans, and 
the relevant costs of providing such protection [19, 22, 
24–26].
Currently there are four classes of insecticides approved 
for use in IRS formats: organochlorines, organophos-
phates, carbamates, and pyrethroids [27], but only the 
pyrethroids are considered safe enough for use in LLINs. 
The wide-scale deployment of pyrethroids in both LLIN 
and IRS formats has undoubtedly exerted considerable 
selection pressure upon vector populations, resulting in 
the rapid and widespread emergence of physiological 
resistance to these active ingredients, which may nega-
tively influence the efficacy of LLINs in particular [28]. As 
a consequence, the World Health Organization (WHO) 
recommends a reduction in use of pyrethroids for IRS, 
particularly in areas where LLIN deployment has been 
scaled up to reach high coverage [29, 30]. Furthermore, 
IRS application of multiple insecticides from different 
classes, ideally with complementary modes of action and 
non-overlapping resistance mechanisms, in rotations or 
mosaics is recommended as the optimal means of insec-
ticide resistance management in the short-to-medium 
term [28]. Unfortunately, the utilization of organochlo-
rines for IRS, particularly DDT, has been discouraged and 
scaled down due to concerns about potentially negative 
environmental effects associated with their use [31]. The 
remaining recommended formulations of organophos-
phates and carbamates have not been extensively used 
in IRS programmes due to their comparatively high cost 
and relatively short residual periods of approximately 
2–6 months [27], which necessitates spraying more than 
once in areas with protracted transmission seasons or 
perennial transmission. Fortunately, new formulations 
of the organophosphate pirimiphos methyl (PM) have 
been brought to market for public health use that appear 
Conclusion: Where universal coverage targets for LLIN utilization has been achieved, supplementing LLINs with IRS 
using pyrethroids may reduce malaria transmission below levels achieved by LLIN use alone, even in settings where 
pyrethroid resistance occurs in the vector population. However, far greater reduction of transmission can be achieved 
under such conditions by supplementing LLINs with IRS using non-pyrethroid insecticide classes, such as organo-
phosphates, so this is a viable approach to mitigating and managing pyrethroid resistance.
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to offer increased and prolonged efficacy, notably against 
pyrethroid-resistant vectors [32, 33].
Given the substantial additional cost of supplement-
ing LLINs with IRS, especially with such expensive 
new insecticides, and the persisting controversy about 
whether incremental protection against malaria is 
accrued, it is important to directly evaluate such combi-
nations at community-level with epidemiological primary 
outcomes and explanatory entomological secondary out-
comes in representative malaria-endemic settings. Thus, 
the overall aim of the study was to evaluate the incre-
mental impact of supplementary vector control with IRS 
upon malaria transmission by the widespread and highly 
efficient African vector Anopheles funestus in a study area 
with relatively high usage rates of pyrethroid-impreg-
nated LLINs, using either one of two different formula-
tions of pyrethroids, or one of two different formulations 
of the new PM organophosphate.
Methods
Study area
The study was conducted in the predominantly rural dis-
tricts of Luangwa and Nyimba, located in Lusaka and 
Eastern provinces, respectively, of the Republic of Zam-
bia (Fig. 1).
These districts have perennial transmission of Plasmo-
dium falciparum, with the overwhelmingly predominant 
vector being An. funestus, which mediates a mean ento-
mological inoculation rate (EIR) for non-users of LLINs 
of approximately 70 infectious bites per unprotected per-
son per year [34]. The district of Luangwa (3468 sq km) 
is located 350–500 m above sea level, 325 km southeast 
of Lusaka, the capital city of Zambia. It has a population 
of approximately 27,560 residents, with an annual growth 
rate of 2.9  % [35]. The main economic activities in the 
district are fishing and agriculture. Nyimba is a larger 
district (10,943 sq km), with a population of 108,637 
inhabitants and an annual growth rate of 3.4 % [35]. The 
district is located 400–1200  m above sea level, 350  km 
east of Lusaka. Agriculture is the predominant economic 
activity in Nyimba district.
Study design
In each district, seven clusters of approximately 165 
households were selected and enrolled in the study to 
participate in longitudinal parasite surveys [36]. Of these, 
15 households in each cluster were selected and enrolled 
at the discretion of the community health worker 
(CHW), so that they were geographically distributed 
across the cluster, for participation in monthly entomo-
logical observations, with the exception of Luangwa High 
School, where 30 households were enrolled. Both parasi-
tological and entomological assessments were conducted 
continuously from January 2011 to March 2013 in 
Luangwa and from April 2011 to March 2013 in Nyimba 
district in all clusters.
The pyrethroid deltamethrin [wettable granule (WG) 
formulation] was sprayed in all consenting households 
at the four southernmost clusters in Luangwa in October 
2010, immediately before that year’s rainy season and ini-
tiation of this study. During the study period, three other 
selected IRS insecticide treatments [capsule suspension 
(CS) formulation of the pyrethroid lambdacyhalothrin, 
as well as the emulsifiable concentrate (EC) and CS for-
mulations of the organophosphate pirimiphos methyl 
(PM)] were randomly allocated to clusters in advance of 
each rainy season. In practice this randomized allocation 
was not strictly adhered to by the implementation agen-
cies in the two districts (District Medical Office (DMO) 
in Luangwa and Abt Associates under the supervision 
of the DMO in Nyimba), thus resulting in a quasi-rand-
omized study design, described cartographically in Fig. 1. 
The parasitological and entomological surveys were con-
ducted by paid CHWs as previously described [34, 36] 
and summarized below. In the south of Luangwa district, 
between October and November 2010, clusters 4, 5, 6, 
and 7 received pyrethroid-based IRS with deltamethrin 
(K-Othrine WG® 250, Bayer Environmental Science, 
South Africa) as described in Fig.  1a. Subsequently, the 
organophosphate PM was introduced as an alternative 
insecticide for IRS in a response to detection of resist-
ance to pyrethroids in the primary vector, An. funestus 
in Luangwa district [37–39]. The only formulation of PM 
that was available at the time was the relatively short-
lived [33, 40] EC formulation (Actellic® EC, Syngenta 
Crop Protection AG, Switzerland). This formulation 
was sprayed during the months of October and Novem-
ber 2011, in clusters 2, 4, 5 in Luangwa and 9, 11, 13 in 
Nyimba, while IRS with pyrethroid lambdacyhalothrin 
(Icon® 10 CS formulation, Syngenta Crop Protection AG, 
Switzerland) was applied in only two of the four clusters 
in the south of Luangwa district which had been sprayed 
with deltamethrin the previous year, specifically in clus-
ters 6 and 7 (Fig.  1b). The following year, in November 
2012, the longer-lasting microencapsulated formulation 
of PM (Actellic® 300CS, Syngenta Crop Protection AG, 
South Africa) was applied in clusters 8, 9, 10, 12, and 14, 
all of which were in Nyimba district (Fig. 1c). In Febru-
ary 2013, IRS in Luangwa district was implemented 
with PM-EC in clusters 2, 4 and 5 while clusters 6 and 
7 received the CS formulation of lambdacyhalothrin 
(Fig. 1d).
Parasitological surveys of human infection
Active monthly parasitological surveys were coupled with 
questionnaires recording clinical symptoms of illness, 
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LLINs  + IRS (Deltamethrin WG) 
LLINs  + IRS (Lambdacyhalothrin  CS) LLINs  + IRS (CS Pirimiphos methyl ) 
LLINs  + IRS (EC Pirimiphos methyl) 
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Fig. 1 Map indicating location of health facilities and associated catchment populations enrolled in the study, with allocation of IRS treatments 
per cluster and year [a LLINs + IRS (deltamethrin WG); b LLINs + IRS (EC pirimiphos methyl or lambdacyhalothrin CS); c LLINs + IRS (EC pirimiphos 
methyl or CS pirimiphos methyl or lambdacyhalothrin CS); and d LLINs + IRS (EC pirimiphos methyl or lambdacyhalothrin CS)]
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as well as access and utilization of preventive measures 
such as LLINs, IRS and intermittent preventive therapy 
(IPT), between January 2011 and May 2013, spanning a 
period of approximately 29  months, as described previ-
ously [36]. These surveys were conducted by paid CHWs 
who made active monthly visits to households that con-
sented to participate in the study. In between active vis-
its, study participants who developed symptoms were 
encouraged to seek care through passively offered diag-
nosis and treatment services, either from the CHWs at 
their place of residence or at the nearest health facility. 
The rapid diagnostic test used in the study was manu-
factured by ICT Diagnostics to detect circulating P. fal-
ciparum histidine-rich protein-2 antigen (ICT Malaria 
P.f. cassette test). All participants that were found posi-
tive for antigenaemia, which was presumed equivalent 
to infection, were treated with artemether-lumefantrine 
as per national malaria diagnosis and treatment policy 
[41]. In both the active and passive visits, all participants 
found to be negative for malaria infection but febrile or 
had any other complaints, were referred to the nearest 
health facility.
Mosquito densities and species identification surveys
The monthly mosquito collections were conducted by 
paid CHWs using Centres for Disease Control and Pre-
vention light traps (LT) and Ifakara tent traps (ITT) 
between January 2010 and April 2013, spanning a period 
of approximately 28 months, as described previously [34].
Fifteen well-distributed houses were semi-arbitrarily 
selected for mosquito trapping in each housing cluster, 
with the exception of Luangwa High School which had 30 
houses due to the availability of an extra CHW involved 
in mosquito trapping. Each house was visited once per 
month for mosquito trapping using both the LT and 
ITT, on a consistent date of the month which was pre-
agreed with each consenting household head [34]. In 
each consenting household, the LTs were placed at the 
foot end of an occupied sleeping space covered with an 
LLIN, hanging approximately 1.5  m above the floor. An 
ITT was placed immediately outside, approximately 5 m 
away from the house where the LT was installed and 
was occupied by an adult male volunteer from the same 
household. All the mosquito traps were set up in the 
evenings and collection of the captured mosquitoes was 
done in the early morning by aspiration. All the collected 
mosquitoes were initially sorted in the field to genus 
level by the CHWs, based on crude taxonomic features 
and then stored over silica until they were collected on a 
monthly basis and transported to a central laboratory at 
the National Malaria Control Centre (NMCC) for further 
detailed examination. Additional morphological iden-
tification of Anopheles to species group or complex [42] 
was conducted at the central laboratory of the NMCC in 
Lusaka. Polymerase chain reaction (PCR) for the identi-
fication of species within the An. funestus group [43] or 
An. gambiae complex [44] were conducted on selected 
samples in the NMCC laboratory.
Vector susceptibility to different classes of insecticides
A team of trained entomological technicians from the 
NMCC periodically collected samples from the study 
sites to ascertain the susceptibility of the mosquitoes to 
different classes of insecticides, as background descrip-
tive data to support appropriate interpretation of appar-
ent impacts of various supplementary IRS treatments 
upon the vector population. In Luangwa district, mos-
quitoes were collected from cluster 2 from 2010 to 2013. 
However, in Nyimba district, collections were done over 
3  years in different clusters (cluster 14 in 2011, clus-
ter 9 in 2012 and cluster 13 in 2013). Adult mosquitoes 
were either collected while attacking humans by human 
landing catch (HLC) or by using pack aspirators for the 
indoor wall-resting mosquitoes. These were collected in 
cups covered with a netting material and placed in cooler 
box for transportation to the NMCC insectary where 
individual female An. funestus mosquitoes where allowed 
to feed on mouse blood so they could lay eggs that were 
then reared into F1 generation mosquitoes. Standard 
WHO susceptibility tests using insecticide-impregnated 
papers with discriminatory dosages of two pyrethroids 
(deltamethrin 0.05  % and lambdacyhalothrin 0.05  %), 
a carbamate (bendiocarb 0.1  %), an organophosphate 
(malathion 0.4 %) and an organochlorine (DDT 4 %) were 
carried out on 2–5 day-old F1 An. funestus mosquitoes. 
Control papers were impregnated with oil as directed by 
the WHO protocol [45]. Knock-down and mortality rates 
after 1 and 24 h post-exposure periods were recorded.
Indoor‑outdoor distribution of human exposure 
to Anopheles funestus bites
To estimate proportions of human exposure to An. funes-
tus bites and malaria transmission that occurs indoors 
and outdoors, HLCs were conducted both indoors and 
outdoors by a team of trained entomological techni-
cians from the NMCC in Lusaka and these were comple-
mented by cross-sectional questionnaire surveys of when 
residents went indoors for the night, went to sleep, awoke 
in the morning, and left the house in the morning, as 
previous described [39], again as background descriptive 
data to support appropriate interpretation of apparent 
impacts of various supplementary IRS treatments upon 
the vector population and malaria transmission. Trained 
CHWs conducted HLC from 18.00 to 06.00  h, with the 
exception of the previously described 2010 studies where 
the starting time was 19.00 and finished at 07.00. The 
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2010 and 2011 HLC surveys were conducted in cluster 4 
(Chisobe and Nyamumba villages of Luangwa district) as 
part of a trap effectiveness study [38], while those con-
ducted in 2012 and 2013, where part of the quality assur-
ance surveys were conducted in 13 clusters as part of a 
subsequent effectiveness assessment for a community-
based trapping scheme [34]. Mosquitoes were collected 
for 45 min per hour to allow a 15-min break for rest and 
refreshment for the collectors. Each hourly collection 
were labelled and kept for identification to genus and 
species as described above. The proportion of time that 
residents spent outdoors and indoors, as well as asleep 
in bed, was estimated directly from answers to question-
naires during a cross-sectional household survey in April 
2010 in Luangwa district, in which people indicated the 
time they usually went indoors and when they went to 
the bed as well as when they arose in the morning and 
when they left their houses [39].
Data management and statistical analysis
The CHW Malaria Register data describing rapid diag-
nostic test (RDT) results associated with questionnaire 
responses were double entered into Excel®, verified, 
reconciled, and then cleaned following descriptive fre-
quency analysis of the distributions of values for each 
variable. All entomological data were single entered, veri-
fied and cleaned prior to analysis. All statistical analyses 
were accomplished using SPSS version 20 (IBM) and R 
version 2.14.1, augmented with the lattice, Matrix and 
LME4 packages.
Incremental protection of humans against malaria 
infection risk by IRS treatments
Previous analyses of these data collected by CHWs 
have demonstrated that diagnostic positivity (DP) for 
malaria infection, expressed as the proportion of RDT-
tested individuals who were found to be positive, was a 
extremely powerful indicator of malaria risk that allowed 
numerous important epidemiological phenomena to be 
clearly illustrated [36]. It also proved to be a more con-
sistent and robust indicator of geographic and temporal 
variation than absolute numbers of malaria infections 
detected, presumably because variations in CHW ser-
vice utilization rates, as well as RDT and ACT availability, 
occur in both the nominator and denominator of DP [46], 
and was therefore treated as the primary epidemiologi-
cal outcome used for statistical analysis of the effects of 
various IRS treatments, rather than incidence in terms of 
detected events per number of participants per unit time.
Four sequential time period categories, based on the 
integer number of months since the most recent spray 
round was completed were created for all the IRS treat-
ments: 1–3, 4–6 and 7–12 months since beginning of the 
last spray round started, as well as a fifth category com-
bining areas that had not yet received spraying during 
the study period and those for which the last spray round 
began more than 12  months ago, which was treated as 
the reference value. Generalized linear mixed models 
(GLMMs) were fitted to evaluate the association between 
observed malaria infection risk among human residents 
and the various IRS treatments applied. Malaria infection 
status was treated as the binary dependent, with use of 
an LLIN, having slept in a house that had been treated 
with IRS in the previous 6  months and the categorized 
cluster-wide IRS treatments as the independent vari-
ables of primary interest. Age category (<1, 1–4, 5–10, 
11–14, 15–24, 25–44 and >45  years of age), sex, sea-
son (hot and wet from December to April, cool and dry 
from May to August, and hot and dry from September 
to November), number of previous RDTs conducted per 
individual and geographical location (cluster) were also 
included as independent variables of secondary interest 
(all categorical except for number of RDTs) while ran-
dom effects to capture variance associated with nuisance 
variables of no direct interest were also included in the 
model (the individual identity number nested within the 
CHW catchment nested within the study cluster, as well 
as date of participant contact). IPT use was not included 
in the final model as an independent variable because it 
had no apparent effect on malaria infection prevalence 
(P  =  0.8633). Further, in order to test for and quantify 
incremental impact of PM IRS as a supplement to LLINs, 
relative to LLINs supplemented with pyrethroid-based 
IRS, both pyrethroid formulations were represented by 
a single treatment variable, coding the same periods of 
months since before spraying. Similarly, in order to test 
for and quantify the incremental impact of the CS formu-
lation of PM, relative to the EC formulation of the same 
active ingredient, as well as the two pyrethroid formu-
lations, an additional variable was created which com-
bined any previous treatment with any of the latter three 
formulations in the reference group. In all cases, incre-
mental protective efficacy (IPE) was calculated as the 
complement of the odds ratio (OR) estimated directly by 
these GLMMs (IPE = 1−OR).
Incremental protection of humans against human 
exposure to mosquito bites and malaria parasite 
inoculation by IRS treatments
The effect of different IRS treatment regimens on den-
sities of An. funestus species were estimated by fitting 
GLMMs where An. funestus densities were treated as a 
dependent variable with a Poisson distribution. In order 
to account for variance in mosquito densities by location, 
identities for households were nested within those vil-
lages and then nested within clusters as random effects. 
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Similarly, nightly temporal variance in vector density 
was accounted for by including date as an additional 
random effect. The different IRS treatment regimens 
were coded in terms of time period since the last round 
of IRS application began, exactly as described above for 
the epidemiological primary outcomes, so that these 
treatments could be included as categorical independ-
ent variables with which to detect and quantify impact 
upon these entomological secondary outcomes. In all, 
the relative rate (RR) at which mosquitoes were captured 
was calculated as estimated directly by these GLMMs. 
Unfortunately, efforts to develop laboratory capacity 
for determining sporozoite infection status by enzyme-
linked immunosorbent assay (ELISA) at NMCC were 
unsuccessful so neither sporozoite prevalence nor ento-
mological inoculation rate could be assessed as addi-
tional entomological secondary outcomes.
Physiological resistance to insecticides
Insecticide susceptibility assays were conducted on 
2–5  day-old F1 generation An. funestus as described by 
the WHO standard protocol [47] using papers impreg-
nated with deltamethrin (0.05  %), lambdacyhalothrin 
(0.05 %), bendiocarb (0.1 %), malathion (0.1 %) or DDT 
(4  %). In order to test for time trends in physiological 
resistance of An. funestus to pyrethroids and carbamates 
over time, survival status of mosquitoes exposed to these 
insecticides in standard WHO protocols [45] was treated 
as the binary outcome variable in GLMMs with year as a 
continuous covariate and a unique identification code for 
each experimental replicate as a random effect. The data 
were stratified into sub-sets on the basis of the insecticide 
class, with separate models fitted for the carbamate (ben-
diocarb), and the combined pyrethroids (deltamethrin 
and lambdacyhalothrin). The model of resistance time 
trends for the two pyrethroids, the identities of these two 
insecticides within this class were included as a categori-
cal independent variable. No such model was fitted for 
either the organochlorine (DDT) or the organophosphate 
(Malathion) because no resistance to either insecticide 
was apparent.
Proportions of human exposure to Anopheles funestus 
bites occurring indoors and outdoors
The distribution of human exposure to An. funestus bites, 
and presumably malaria transmission, across different 
times of the night and across indoor and outdoor com-
partments of their living environment was calculated by 
weighting HLC measurements of indoor and outdoor 
biting rates for each hour of the night by the estimated 
proportion of humans indoors and outdoors during that 
time period, exactly as previously described [39]. These 
estimates of human exposure distribution across indoor 
and outdoor environments were calculated and pre-
sented graphically for both users and non-users of LLINs, 
so that the proportions of human exposure that occur 
indoors in the presence (πi,n) and absence (πi) of a pro-
tective LLIN could be quantified and visualized.
Protection of human participants and ethical approval
Prior to the study, community sensitization was con-
ducted and permission obtained from the local commu-
nity leadership. Informed consent was obtained from 
all study participants during all surveys and spraying 
activities. The study team ensured that all treatment and 
diagnostic protocols were adhered to and that patients 
requiring malaria treatment received it promptly or were 
referred to the nearest health facility. All participants 
who took part in the HLCs gave written consent to par-
ticipate after being informed of the risks and benefits, 
and were provided with weekly prophylaxis using the 
nationally recommended combination drug of 100  mg 
Dapsone and 12.5  mg pyrimethamine (Deltaprim®, 
CAPS Pharmaceuticals, Zimbabwe) so that their overall 
malaria risk was considered to be far lower than it would 
otherwise be in the course of their normal lives if they did 
not participate in the study [48]. All standard safety pro-
tocols for IRS application were adhered to as per national 
guidelines. Ethical approval was obtained from the Uni-
versity of Zambia, Biomedical Research Ethics Com-
mittee (Reference 004-05-09) and the Research Ethics 
Committee of the Liverpool School of Tropical Medicine 
(Approval 09.60). Authority to conduct and publish the 
study was also obtained from the Ministry of Health in 
Lusaka, Zambia.
Results
Characteristics of study participants and survey clusters
A total population of 25,354 people centred around 
health facilities in the 14 clusters participated in the 
study and were followed up for a period of 29 months in 
Luangwa and 26 months in Nyimba, starting from Janu-
ary 2011 and April 2011, respectively. Out of these partic-
ipants, 29 % (7412) were children under the age of 5 years 
but DP peaked in older children between the age of five 
and ten. The overall cluster populations ranged from 1158 
to 3429. A total of 31,974 malaria infections (21.7 % DP) 
were identified, which translates into an incidence of nine 
infections per 100 person years. The study population 
reported a relatively high average rate of LLIN utilization 
of 81.7  % of questionnaire responses over the course of 
the study, indicating that the respondent had slept under 
an LLIN the previous night, while 39.2 % of participant 
questionnaire responses indicated that the respondent’s 
house had been treated by IRS in the last 6 months. Dur-
ing same overall study period mean DP by cluster across 
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all age groups and other potential stratification criteria 
ranged from 6.4 to 41.9 % (mean = 24.5 %), with the low-
est being in the southern urban cluster and the highest 
in the northern rural cluster (Tables 1, 2). The potential 
confounding effect of LLIN ownership was excluded 
from the final model described in Table 2 because it had 
no significant effect (P = 0.7584) on diagnostic positivity.
The close associations of DP for P. falciparum malaria 
infection and An. funestus density, clinical symptoms of 
illness, and a variety of other factors of this setting are 
described in detail elsewhere based on the first year of 
data collection [34, 36]. The detailed profile of the study 
participants, and their survey contacts over the course 
of the entire study, are summarized in the context of the 
study design in Fig. 2.
A descriptive comparison of summarized data 
restricted to the period 1–6 months post-spraying dem-
onstrates variability among study clusters not only in 
IRS coverage (range = 0–100 %, mean = 29.4 %) but also 
LLIN use (range = 6.6–100 %, mean = 68.2 %) and diag-
nostic positivity (range =  2.99–61.9  %, mean =  25.4  %) 
(Table  1; Additional file  1). Further analysis using Pear-
son’s correlation, revealed a positive but weak asso-
ciation (r2 = 0.31) between IRS coverage and LLIN use, 
suggesting that as IRS coverage increases, so does LLIN 
use. However, this does not necessarily imply any causal 
relationship and factors which affect delivery (e.g., acces-
sibility) and acceptance (e.g., attitudes towards malaria or 
mosquitoes) may well be similar for both of these vector 
control measures. However, there was no obvious and 
clear-cut effect of any particular IRS treatment in this 
crude descriptive comparison (Table 1; Additional file 1) 
so detailed regression modelling analysis was required 
to detect and estimate the separate impacts of these four 
different formulations (Table 2, Figs. 3, 4, 5).
Magnitude and duration of incremental impact of IRS 
treatments as supplements to LLINs upon human risk 
of infection with malaria
Reported coverage of deltamethrin WG, lambdacyhalo-
thrin CS, PM EC, and PM CS, by respondents within 
the first 3  months after their application in clusters to 
which they were assigned was 82  % (2132/2599), 61  % 
(2068/3384), 53 % (5909/11,078), and 69 % (2716/3913), 
respectively. Over the study period, DP ranged from 13.3 
to 23.8 % (mean = 18.4 %), 4.5 to 22.7 % (mean = 10.3 %), 
16.0 to 28.8  % (mean  =  21.4  %) and 13.0 to 49.5  % 
(mean  =  28.7  %) for clusters assigned with deltame-
thrin WG, lambdacyhalothrin CS, PM EC, and PM CS 
respectively (Tables 1, 2). As illustrated in Fig. 3, PM CS 
conferred the strongest initial incremental protection in 
the first 3 months after application (IPE [95 % CI = 0.63 
[0.57, 0.69], P < 0.001), relative to LLINs alone, followed 
by the CS formulation of lambdacyhalothrin (IPE [95 % 
CI]  =  0.31 [10, 47], P  =  0.006), the EC formulation of 
PM (IPE [95 % CI] = 0.23 [0.15, 0.31], P < 0.001) and the 
WP formulation of deltamethrin (IPE [95  % CI] =  0.19 
[−0.01, 0.35], P  =  0.064). However, neither pyrethroid 
formulation provided any incremental protection beyond 
3 months post-application, while the incremental protec-
tion provided by CS and EC formulations of PM persisted 
undiminished for 6 and 12 months, respectively (Fig. 3).
Table 1 Trends in  RDT-determined diagnostic positivity (DP) at  each cluster over  time as  different IRS treatments were 
applied
Cluster October 2010–March 2011 October 2011–March 2012 October 2012–March 2013
IRS treatment DP % (n/N) IRS treatment DP % (n/N) IRS treatment DP % (n/N)
1 None 24.7 (372/1508) None 9.5 (95/998) None 14.4 (150/1039)
2 None 20.9 (559/2676) Pirimiphosmethyl EC 8.5 (280/3292) None 11.9 (126/1061)
3 None 26.9 (809/3006) None 10.8 (436/4033) None 14.1 (282/2004)
4 Deltamethrin WG 33.2 (825/2489) Pirimiphosmethyl EC 5.9 (217/3708) Pirimiphosmethyl EC 10.8 (314/2908)
5 Deltamethrin WG 27.5 (396/1439) Pirimiphosmethyl EC 18.2 (624/3436) Pirimiphosmethyl EC 27.3 (456/1673)
6 Deltamethrin WG 11.9 (338/2845) Lambdacyhalothrin CS 5.2 (76/1457) Lambdacyhalothrin CS 3.8 (57/1505)
7 Deltamethrin WG 6.0 (144/2415) Lambdacyhalothrin CS 4.2 (130/3111) Lambdacyhalothrin CS 2.99 (33/1105)
8 None 55.7 (202/363) None 29.9 (974/3261) Pirimiphosmethyl CS 9.0 (209/2321)
9 None 36.4 (4/11) Pirimiphosmethyl EC 46.6 (684/1467) Pirimiphosmethyl CS 23.5 (366/1561)
10 None 50.7 (172/339) None 35.4 (444/1254) Pirimiphosmethyl CS 27.1 (363/1341)
11 None 51.3 (60/117) Pirimiphosmethyl EC 30.2 (941/3112) None 11.9 (300/2531)
12 None 61.9 (26/42) None 33.9 (514/1517) Pirimiphosmethyl CS 21.7 (246/1132)
13 None 60.0 (120/200) Pirimiphosmethyl EC 27 (5.033/1974) None 30.6 (666/2180)
14 None 52.4 (33/63) None 41.3 (786/1904) Pirimiphosmethyl CS 16.99 (221/1301)
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Table 2 Association of malaria infection status with age, sex, LLINs, IRS, number of tests conducted per participant, geo-
graphical location, season and IRS insecticide used
Category DP % N/N (I) OR [95 % CI] P
Overall 21.7 31,974/147,257 (25,354) 0.13 [0.08, 0.21] <0.001
Age
 <1 14.2 501/3535 (1735) 1.26 [1.09, 1.45] 0.001
 1–4 24.0 6127/25,505 (5677) 2.75 [2.54, 2.98] <0.001
 5–10 27.4 10,066/36,779 (7608) 3.62 [3.35, 3.91] <0.001
 11–14 26.0 4892/18,840 (4746) 3.36 [3.09, 3.65] <0.001
 15–24 20.3 4491/22,077 (5685) 2.04 [1.88, 2.22] <0.001
 25–44 14.9 4028/27,044 (5807) 1.24 [1.14, 1.34] <0.001
 ≥45 13.8 1796/13,027 (2903) 1 [NA] NA
Sex
 Male 23.3 16,068/79,208 (12,008) 1 [NA] NA
 Female 20.3 15,750/67,567 (13,228) 0.86 [0.83, 0.90] <0.001
Interventions
 LLINs 20.0 20,613/103,149 (20,706) 0.89 [0.85, 0.93] <0.001
 IRS 17.4 7568/43,560 (9926) 0.87 [0.82, 0.93] <0.001
 Number of tests conducted per participant 21.7 31,974/147,257(25,354) 0.97 [0.97, 0.98] <0.001
Type of visit
 Passive 43.4 6416/14,785 (8922) 1 [NA] NA
 Active 19.2 25,281/131,359 (22055) 0.29 [0.28, 0.31] <0.001
 Clusters
Luangwa district
Sinyawagora RHC 19.7 1314/6655 (1959) 2.86 [1.65, 4.97] <0.001
Kasinsa RHC 16.7 2232/13,402 (3429) 4.67 [2.78, 7.84] <0.001
Chitope RHC 19.6 3419/17,463 (1215) 2.92 [2.04, 4.17] <0.001
Luangwa High School RHC 16.5 2854/17,320 (1158) 7.37 [4.31, 12.61] <0.001
Mphuka RHC 24.9 2981/11,957 (2147) 7.37 [4.31, 12.61] <0.001
Mandombe RHC 10.3 1386/13,508 (1805) 1.54 [0.89, 2.66] 0.119
Luangwa Boma RHC 6.4 839/13,161 (2033) 1 [NA] NA
Nyimba district
Kacholola RHC 26.7 3108/11,654 (1166) 7.50 [4.75, 11.84] <0.001
Hofmeyer RHC 41.9 2601/6214 (2120) 15.81 [10.20, 24.52] <0.001
Mtilizi RHC 37.6 2238/5949 (2024) 12.35 [7.72, 19.76] <0.001
Mtilizi RHP 25.3 2478/9788 (3379) 13.49 [8.45, 21.56] <0.001
Chinambi RHC 31.9 1740/5463 (1741) 9.16 [5.79, 14.48] <0.001
Mkopeka RHC 32.8 2761/8413 (1311) 14.22 [8.55, 23.63] <0.001
Chipembe RHC 32.1 2023/6310 (1916) 13.54 [8.03, 22.84] <0.001
Season
 Hot & wet (Dec–April) 25.3 18,283/72,217 (20,243) 4.20 [3.67, 4.81] <0.001
 Cool & dry (May–Aug) 23.9 11,216/46,860 (16,513) 3.25 [2.80, 3.76] <0.001
 Hot & dry (Sept–Nov) 8.7 2444/27,983 (12,590) 1 [NA] NA
Insecticide applied for IRS
Deltamethrine
1–3 months since last spray 13.3 322/2419 (2166) 0.81 [0.65, 1.01] 0.064
4–6 months since last spray 23.8 2411/10,150 (4231) 1.07 [0.94, 1.23] 0.295
7–12 months since last spray 13.6 2128/15,640 (4434) 1.16 [1.03, 1.30] 0.013
Never sprayed and >13 months since last spray 22.8 27,083/118,899 (23,233) 1 [NA] NA
Lambdacyhalothrin
1–3 months since last spray 4.7 145/3102 (1526) 0.69 [0.53, 0.90] 0.006
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The first 3  months after IRS with the CS formulation 
of PM offered greater protection against malaria infec-
tion than IRS with pyrethroids IPE [95  % CI]  =  0.51 
[0.38, 0.62], P < 0.001 for LLINs + IRS with PM-CS com-
pared to LLINs +  IRS in all clusters treated with either 
DM-WG or LC-CS but not PM-EC (P  <  0.001). The 
incremental protection against malaria infection by IRS 
with both PM formulations outlasted both pyrethroid 
formulations so that they both offered greater protec-
tion from 4 to 6  months post-application IPE [95  % 
CI] = 0.79 [0.75, 0.83], P < 0.001 for LLINs +  IRS with 
PM-CS and IPE [95 % CI] = 0.42 [0.33, 0.48], P < 0.001 
for LLINs + IRS with PM-EC, compared to LLINs + IRS 
with either DM-WG or LC-CS) (Fig. 4).
Beyond 6 months post-application, LLINs plus IRS with 
PM-CS provided no apparent incremental protection rel-
ative to LLINs alone (P = 0.204), much less LLINs + IRS 
with pyrethroids (P = 0.432). However, LLINs + PM-EC 
continued to provide incremental protection relative to 
not only LLINs alone (Fig. 3), but also relative to all other 
LLIN + IRS treatments (IPE [95 % CI] = 0.41 [0.34, 0.48], 
P < 0.001). When the duration of efficacy of PM-EC was 
examined in further detail by breaking down the third 
post-spray time period into two halves, it was clear that it 
lasted approximately a full year because similar levels of 
incremental protection was confirmed for both the seven 
and 9  months post-spray period (IPE [95  % CI]  =  0.32 
[0.22, 0.40], P  <  0.001) and the 10 to 12  months post-
spray period (IPE [95 % CI] = 0.42 [0.31, 0.52], P < 0.001).
Comparing these two IRS formulations of PM with 
each other as supplements to LLINs, the CS formula-
tion confers greater protection than the EC formulation, 
(IPE [95 % CI] = 53.6 [0.43, 0.66]  %, P < 0.001 from 1 to 
3 months post-application and 0.64 [0.57, 0.69], P < 0.001 
from 4 to 6  months post-application for the contrast 
between LLINs + PM-CS versus the LLIN + PM-EC as 
the reference group) (Fig.  5). However, once the incre-
mental benefit of supplementing LLINs with IRS using 
PM-CS waned after 6 months, IRS using PM-EC proved 
statistically superior to all other IRS formulations as sup-
plements to LLINs for a further 6 months, including the 
CS formulation of the same active ingredient (IPE [95 % 
CI] = 0.52 [0.21, 0.70], P < 0.001 for the contrast between 
LLINs  +  PM-EC versus LLIN  +  PM-CS as a reference 
group between seven and 12 months post-application).
Magnitude and duration of incremental impact of IRS 
treatments as supplements to LLINs upon human risk 
of exposure to bites of Anopheles funestus
Detailed description of the local mosquito fauna in 
the study area [34] showed that 34.5  % of all mosqui-
toes caught over the course of the study were identified 
morphologically as members of the An. funestus group, 
of which 96.5  % (575/596) of those which were suc-
cessfully amplified by PCR, were confirmed to be An. 
funestus. Densities of the An. funestus group, as deter-
mined by routine morphological classification can there-
fore be considered quite reliable, as of An. funestus, the 
The association of malaria infection with age, sex, use of LLINs, use of IRS, geographical location (cluster), number of tests conducted per participant, season and 
insecticide used in IRS was determined using GLMM; with observed malaria RDT determined status as a binary dependent outcome with the independent categories 
of age, sex, access and use of LLINs or IRS, insecticide used in IRS, number of tested conducted per participant and seasons. The models included date and participant 
nested within CHW catchment nested within geographical location (cluster) as random effects except for one in which cluster was treated as a categorical variable to 
determine the effects of each cluster. The final model consisted of age, sex, access and use of LLINs or IRS, insecticide used in IRS, season, number of tests conducted 
per participant and geographical location as the determinants of malaria infection
DP RDT-determined diagnostic positivity, n Number RDT positive, N Total number tested by RDT, I Number of individuals that participated in RDT testing, OR Odds 
ratio, CI Confidence intervals, P Probability of the null hypothesis, NA Not applicable because reference group
Table 2 continued
Category DP % N/N (I) OR [95 % CI] P
4–6 months since last spray 9.4 207/2199 (1264) 1.26 [1.01, 1.57] 0.042
7–12 months since last spray 4.5 157/3508 (1469) 0.94 [0.74, 1.21] 0.653
Never sprayed and >13 months since last spray 22.7 31,435/138,299 (24,931) 1 [NA] NA
Primiphosmethyl EC
1–3 months since last spray 18.9 1922/10,194 (5527) 0.77 [0.69, 0.85] <0.001
4–6 months since last spray 28.8 2666/9259 (5926) 0.64 [0.58, 0.71] <0.001
7–12 months since last spray 16.0 1793/11,184 (5760) 0.63 [0.56, 0.71] <0.001
Never sprayed and >13 months since last spray 21.9 25,563/11,6471 (22,311) 1 [NA] NA
Primiphosmethyl CS
1–3 months since last spray 13.0 468/3590 (2675) 0.37 [0.31, 0.43] <0.001
4–6 months since last spray 30.6 1386/4536 (3349) 0.24 [0.21, 0.27] <0.001
7–12 months since last spray 49.5 95/192 (191) 1.35 [0.85, 2.15] 0.204
Never sprayed and >13 months since last spray 21.6 29,995/138,790 (24,588) 1 [NA] NA
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abundance of which is consistent with previous studies 
in this area [38, 39] indicating it as the overwhelmingly 
dominant vector of malaria in these two districts of Zam-
bia. Therefore, subsequently in this report all mosquitoes 
caught from the An. funestus group are the nominate 
species in the strict sense.
The relative rates and the mean catches of An. funes-
tus per IRS treatment are presented in Table 3. Relative 
to the times and places that had never been sprayed, or 
sprayed or had been sprayed >12  months previously, 
there were no obvious differences in the densities of 
An. funestus during the first 3  months post-spraying 
26 health facilies assessed for eligibility 
12 excluded because did not 
meet inclusion criteria  
14 clusters established around selected health 
facilies  and assigned to IRS treatment 
10 clusters in Luangwa and Nyimba No IRS in 
previous season  
Clusters: 1,2,3,8,9,10.11.12,13,14 
Individuals: 49300 
Tests through Acve visits:43452 
Tests through passive visits :4500 
Person nights of mosquito trapping with CDC-LT and 
ITT respecvely : 588 & 38 




Tests through Acve visits: 30917 
Tests through passive visits : 3818 
Person nights of mosquito trapping with CDC-LT and 
ITT respecvely : 454 & 30 
2 clusters in Luangwa 
treated with CS-LC 
Clusters:6,7 
Individuals:8268 
Tests through Acve 
visits:7887 
Tests through passive visits 
:373 
Person nights of mosquito 
trapping with CDC-LT and 
ITT respecvely : 234 & 234 
2 clusters in Luangwa 
treated with EC-PM 
Clusters:4,5 
Individuals:12460 
Tests through Acve 
visits:10963 
Tests through passive visits 
:1488 
Person nights of mosquito 
trapping with CDC-LT and 
ITT respecvely : 370 & 369 
4 clusters in Luangwa and  
Nyimba treated with EC-PM 
Clusters:2,9,11,13 
Individuals: 19850 
Tests through Acve 
visits:16742 
Tests through passive visits : 
1239 
Person nights of mosquito 
trapping with CDC-LT and 
ITT respecvely : 267 & 268 
6 clusters in Luangwa and 
Nyimba with  no IRS 
Clusters:1,3,8,10,12,14 
Individuals:22060 
Tests through Acve 
visits:19674 
Tests through passive visits 
:1665 
Person nights of mosquito 
trapping with CDC-LT and 
ITT respecvely : 684 & 685 
2 cluster in Luangwa 
treated with CS-LC 
Clusters:6,7 
Individuals:1124 
Tests through Acve 
visits:1016 
Tests through passive visits 
:108 
Person nights of mosquito 
trapping with CDC-LT and 
ITT respecvely : 82 & 83 
2 clusters in Luangwa 
treated with EC-PM 
Clusters:4,5 
Individuals:2600 
Tests through Acve 
visits:2115 
Tests through passive visits 
:485 
Person nights of mosquito 
trapping with CDC-LT and 
ITT respecvely : 141 & 142 
5 clusters in Luangwa and 
Nyimba treated with CS-PM 
Clusters:8,9,10,12,14 
Individuals:6147 
Tests through Acve 
visits:4575 
Tests through passive visits 
:1517 
Person nights of mosquito 
trapping with CDC-LT and 
ITT respecvely : 180 & 177 
5 clusters in Luangwa and 
Nyimba with no IRS 
Clusters:1,2,3,11,13 
Individuals:4994 
Tests through Acve 
visits:4147 
Tests through passive visits 
:462 
Person nights of mosquito 
trapping with CDC-LT and 


























































Fig. 2 Study profile indicating treatments provided to each cluster with associated timelines, population surveyed and persons nights of mosquito 
trapping
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for both pyrethroid formulations (DM-WG (IPE [95  % 
CI]  =  0.01 [−0.56, 0.37], P  =  0.103) and LC-CS (IPE 
[95 % CI] = −0.03 [−0.88, 0.44], P = 0.195) and PM-EC 
(IPE [95 % CI] = −0.04 [−0.30, 0.17], P = 0.103) (Fig. 6, 
Table 3). However, where PM-CS was applied, mosquito 
densities were dramatically reduced during the same 
period of 3  months immediately after spraying (IPE 
[95  % CI]  =  0.93 [0.87, 0.97], P  <  0.001). Between the 
fourth and the sixth month after spraying with DM-WG, 
there was an apparent, but presumably spurious, 3-fold 
increase in An. funestus densities while LC-CS, PM-EC 
and PM-CS achieved 5-, 3- and 71-fold reductions, 
respectively (Table 3). However, from the seventh to 12th 
months after spraying, DM-WG and PM-EC had no obvi-
ous effect on the An. funestus densities, while insufficient 
data were available to examine the incremental impact of 
LC-CS or PM-CS.
Background observations of insecticide resistance 
and human exposure profiles for local Anopheles funestus 
populations
From the outset of the study, An. funestus exhibited high 
level of resistance to both pyrethroids against which 
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Effect of months since before spraying on diagnosc posivity with 95% confidence 
intervals   
Reference (odds rao = 1)  
Fig. 3 The incremental protective efficacy of each of the four IRS treatments on diagnostic positivity for Plasmodium falciparum malaria infec-
tion over several time periods since the last spray round began, relative to clusters that has either never been sprayed or had last been sprayed 
>12 months ago (reference group), estimated exactly as described in Table 1 (a deltamethrin, b lambdacyhalothrin, c EC pirimiphos methyl and d 
CS pirimiphos methyl)
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over the course of the study (P < 0.001). Alarming rates 
of resistance to the carbamate bendiocarb were also 
observed but these did not increase over the course of 
the study (P = 0.565). During this same period, there was 
no evidence of malathion or DDT resistance detected in 
the mosquito populations (Fig. 7).
Throughout the study period, humans lacking LLINs 
were exposed to far more bites by An. funestus indoors 
during the late hours of the night up to the early morn-
ing hours (Fig. 8), consistent with the known behaviour 
of An. funestus across the continent [42, 49]. The vast 
majority potential exposure to bites by this dominant 
vector occurred indoors at times when most individuals 
are asleep (Fig. 8). Even for those using an LLIN to pre-
vent most indoor transmission, most residual human 
exposure to An. funestus bites and presumably malaria 
transmission, occurred indoors, increasing gradually 
from 57 % in 2010 to 71 % by 2013 (Fig. 8).
Discussion
In this setting of high LLIN unitization (>80 %), even the 
modest (0–100  %, mean  =  29.4  %) coverage achieved 
with supplementary IRS conferred an incremental 
protection against malaria parasite infection through 
reduced vector population density, human exposure to 
bites and, presumably, to sporozoite inoculations. Over-
all supplementing of LLINs with IRS using PM-CS gave 
the greatest apparent protection against malaria risk, 
which lasted for a full 6 months, while IRS with PM-EC 
conferred less dramatic protection that was comparable 
with pyrethroids but apparently lasted for one full year. 
Neither of the two pyrethroid formulations exhibited any 
incremental protective effect for more than 3 months, but 
it is notable that LC-CS conferred an apparently greater 
protective effect than DM-WG. These observations that 
quasi-randomly assigned IRS treatments conferred addi-
tional protection when provided as a supplement to LLIN 
utilization, are consistent with a variety of other observa-
tional studies [17, 50], as well as more recent randomized 
controlled studies [51]. The high level of incremental 
impacts observed, despite sometimes mediocre coverage 
with IRS, are actually consistent with the predictions of 
process-explicit models used to support the policy switch 
to universal coverage for both LLINs and IRS [52], espe-
cially for a very anthropophagic mosquito such as An. 
funestus [2], which is even more anthropophagic than the 
An. gambiae species [53] used as an example mosquito in 
that simulation paper.
The high protective effect of PM-CS is also evident in 
the low densities of An. funestus caught in that group. The 
modest and short-lived protective effect of the two pyre-
throid formulations, DM-WG and LC-CS, most probably 
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Fig. 4 The incremental protective efficacy of pirimiphos methyl 
EC and CS IRS treatments on diagnostic positivity for Plasmodium 
falciparum malaria infection over several time periods since the last 
spray round began, relative to clusters that have been sprayed with 
either deltamethrin and/or lambdacyhalothrin (reference group), 
estimated exactly as described in Table 2, except that three separate 
models were fitted for the three different time periods since the last 
spray round began, and the combined pyrethroid formulations were 
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Fig. 5 The incremental protective efficacy of pirimiphos methyl EC 
IRS treatment on diagnostic positivity for Plasmodium falciparum 
malaria infection over several time periods since the last spray round 
began, relative to clusters that have been sprayed with pirimiphos 
methyl EC (reference group), estimated exactly as described in 
Table 2, except that three separate models were fitted for the three 
different time periods since the last spray round began and the EC 
formulation of pirimiphos methyl was treated as the reference group
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the An. funestus population present in this study area, 
consistent with evidence from Benin in west Africa that 
the protective effect of these insecticide formulations 
can be dramatically reduced to as little as a month by 
physiological resistance, even where these specific for-
mulations have a residual activity against susceptible, 
insectary-reared, mosquitoes for up to 6  months [33]. 
While this rapid loss of incremental protection towards 
malaria elimination with pyrethroid-based supplemen-
tary IRS is of obvious and very direct concern [54–56], 
the encouraging results obtained with IRS using PM, the 
CS formulation in particular, provide further evidence 
that pyrethroid resistance may be mitigated and man-
aged in areas of high LLIN coverage using IRS [20, 51], 
or alternatively impregnating wall linings [57, 58] with 
non-pyrethroids selected on the basis of standard WHO 
susceptibility assays. These observations are therefore 
consistent with similar recent reports from several dis-
tinct settings across Africa [51, 59–61] and can be readily 
rationalized on the basis of the combined observations of 
strong resistance to pyrethroids, complete susceptibility 
to organophosphates, and strong tendency to feed and 
presumably rest indoors among the local An. funestus 
population.
It was expected that PM-CS would be the most per-
sistent because this micro-encapsulated formulation 
is known to confer residual longevity for 6  months [33, 
40] as confirmed here. However, it was surprising that 
PM-EC had the longest longevity on these surfaces, 
apparently lasting 12  months after spraying, contrary 
to other studies suggesting that PM-EC is ineffective on 
mud surfaces [40] and WHO estimates of a residual effect 
of only 3  months [62] but is consistent with one other 
recent study [63]. While it is possible to speculate that 
the persistence of PM-EC may have resulted from an ini-
tial absorption into the porous mud walls in most of the 
houses in the study areas, followed by slow subsequent 
release, it is also possible that this is simply the result of a 
spurious model fit to data from such a limited number of 
treated clusters with considerable intercluster variation 
Table 3 Association of  Anopheles funestus densities with  different IRS insecticides supplementing LLINs upon  months 
before, during and when not spraying
NA Not applicable because reference group, NE Not estimable because no spraying of this insecticide regimen was conducted early enough to yield impact data 
beyond 6 months post-spray but before the following spray round so no data are available for estimation
a The effect of different IRS treatment regimens on the mean catches of An. funestus species where estimated by fitting generalized linear mixed models (GLMMs) 
with An. funestus catches treated as dependent variables. The households where nested within villages which were also nested within the clusters, these together with 
date were treated as random effects, while the different IRS treatment regimens were categorized as independent variables. A Poisson distribution with no intercept 
was used to estimate the mean catches while an intercept was included in estimating the RR
Indoor residual spraying insecticide  
treatment regimen
Absolute numbers  
caught
Mean catchesa Relative biting rates of An. funestus
[95 % Confidence  
interval (CI)]
(RR)a [95 % CI] P value
Deltamethrin WG)
 1–3 months since last spray 73 0.112 [0.641, 0.371] 0.99 [0.63, 1.56] 0.897
 4–6 months since last spray 1229 0.641 [0.371, 1.109] 3.98 [3.15, 5.04] <0.001
 7–12 months since last spray 134 0.111 [0.062, 0.199] 0.86 [0.64, 1.17] 0.067
 >12 months since last spray or never 1186 0.189 [0.113, 0.317] 1 [NA]b NAb
Lambdacyhalothrin CS
 1–3 months since last spray 20 0.191 [0.090, 0.405] 1.03 [0.56, 1.88] 0.805
 4–6 months since last spray 6 0.055 [0.022, 0.141] 0.17 [0.08, 0.39] <0.001
 7–12 months since last spray 0 NEc NEc 0.972
 >12 months since last spray or never 182 0.198 [0.121] 1 [NA]b NAb
Pirimiphosmethyl EC
 1–3 months since last spray 478 0.234 [0.131, 0.417] 1.04 [0.83, 1.30] 0.786
 4–6 months since last spray 346 0.055 [0.030, 0.098] 0.25 [0.20, 0.33] <0.001
 7–12 months since last spray 160 0.159 [0.086, 0.293] 0.69 [0.50, 0.95] 0.151
 >12 months since last spray or never 2823 0.234 [0.131, 0.417] 1 [NA]b NAb
Pirimiphosmethyl CS
 1–3 months since last spray 14 0.021 [0.009, 0.047] 0.07 [0.04, 0.13] <0.001
 4–6 months since last spray 70 0.004 [0.002, 0.008] 0.02 [0.01, 0.02] <0.001
 7–12 months since last spray NEc NEc NEc NEc
 >12 months since last spray or never 2087 0.253 [0.152, 0.422] 1 [NA]b NA
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in malaria risk level and seasonality, as presumably 
occurred for DM-WG, which is highly unlikely to have 
really increased malaria transmission (Fig.  3, Table  2) 
or vector density (Fig.  6, Table  3). The observation that 
impact of both PM formulations and LC-CS upon vec-
tor density was greatest between 4 and 6  months after 
spraying suggests that maximum impact upon the vector 
population required sustained impact upon several gen-
erations of mosquitoes, well into the peak rainy season 
when they would be expected to grow exponentially and 
improve in reproductive fitness as the availability of lar-
val habitat rapidly increases [64, 65].
Of course, there are several substantive limitations 
to this study. While the community-based nature of 
both the parasitological and entomological surveys, 
Fig. 6 The incremental protective efficacy of each of the four IRS treatments against Anopheles funestus bites over several time periods since the last 
spray round began, relative to clusters that has either never been sprayed or had last been sprayed >12 months ago (reference group), estimated 
exactly as described in Table 3 (ND Not done)
Deltamethrin (0.05%) Lambdacyhaothlin  (0.05%) 
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Fig. 7 Insecticide resistance profile of Anopheles funestus in the study 
site from 2010 to 2013
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with only modest supervision and quality assurance, 
does leave some uncertainties about the data quality, 
recent detailed analyses of these primary [36, 46] and 
secondary outcomes [34] provide reassuring confirma-
tion of their epidemiological relevance and discrimina-
tive power. An additional limitation lies in the lack of a 
comprehensive quality assurance system for the RDTs 
results, comparing them with better-established tests, 
such as microscopy, or more sensitive diagnostic tests, 
such as polymerase chain reaction. In spite of the known 
limitations in the sensitivity of RDTs [66], it is encourag-
ing that this specific test kit product, applied in exactly 
the manner described here, proved a robust means of 
monitoring infection and disease burden [36, 46]. While 
this study did not explicitly or comprehensively track 
the distinct costs of IRS and LLINs, these costs may be 
assumed to be incurred largely independently of each 
other because of their distinct delivery methods, and 
have already been evaluated in detail across a variety of 
settings by other authors [12, 26, 67, 68]. However, the 
most obvious limitation of this study is that it was not 
conducted as a rigorous randomized control trial and 
that deviations from the original randomization plan 
resulted in only a quasi-randomized design in practice, 
with known selection biases. This was also coupled with 
a lack of a statically estimated sample size. An addi-
tional considerable limitation arising from dependency 
on delivery of supplementary IRS through routine pro-
grammatic implementation mechanisms was the lack of 
consistent availability of a single, optimal formulation 
of a single pyrethroid or a single formulation of PM, so 
the study was unfortunately fragmented into more treat-
ment arms with smaller numbers of assigned clusters 
per spray round than originally planned. Also, delays 
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Fig. 8 Mean exposure of humans to Anopheles funestus bites when they are indoors or outdoors where πi is the average proportion of human 
exposure to bites of the Anopheles funestus which occurs indoors in the absence of any protective measure, πs is the average proportion of human 
exposure to bites of the Anopheles funestus population which occurs indoors when individuals are asleep in the absence of any protective measure, 
and πi,n is the average proportion of residual human exposure for users of net which occurs indoors, calculated exactly as previously described [39]
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and limitations in the availability of PM formulations in 
the final year of the study resulted in a mismatch in the 
timing of application of PM-CS in Nyimba (November 
2012), PM-EC and LC-CS (both February 2013).
So, in summary this study was not fully randomized 
because the implementation contractors did not fully 
adhere to the study design stipulated to them by the 
NMCC. This study may therefore be described as a quasi-
randomized experimental evaluation to generate plausible 
evidence that the IRS treatments provide effective incre-
mental impact beyond that already provided by high cov-
erage with LLINs under near-programmatic conditions. 
The biggest inherent limitation of observational studies 
is their vulnerability to selection bias and confounding 
[69, 70]. The study largely adhered to its original rand-
omization plan, and some of the most confounding vari-
ables were taken into consideration during planning and 
implementation (stratification of clusters into those that 
had previously been sprayed with deltamethrin and those 
that had not) and analysis (additional variables in regres-
sion models) phases. However, the deviations from the 
randomization plan by the implementing agencies were 
specifically necessitated by product stock availability and 
motivated by efforts to target IRS to areas where they felt 
it was needed most, so treatment allocation was clearly 
systematically biased a priori in these cases. It is therefore 
prudent to interpret the level of evidence generated con-
servatively, and to classify this study as being essentially 
observational in nature. To generate probable evidence 
of efficacy under more precisely controlled (if somewhat 
less programmatically relevant [71, 72]) conditions would 
have entailed a rigorous, fully-randomized trial with a 
registered protocol including sample size estimates, data 
quality assurance and oversight committees [71–74].
While the shortcomings of this study must be accepted, 
there is no obvious specific reason to suggest that they 
are inaccurate, and they do contribute to a relatively lim-
ited evidence base regarding the incremental impact of 
IRS formulations as supplements to LLINs [21]. Despite 
these study design limitations, the evidence generated 
remains useful for guiding programmatic selection of IRS 
treatments. Perhaps just as important, it represents the 
first effort of the NMCC itself, rather than its specialist 
research and academic partner institutions, to conduct a 
cluster-randomized experimental evaluation of malaria 
transmission control measures. It represents, therefore, 
an invaluable experience through which the capacity of 
the NMCC has grown and can hopefully build upon.
Conclusion
Despite these study limitations, the results presented 
here do provide substantial evidence that: (1) supple-
menting pyrethroid-based LLINs with pyrethroid-based 
IRS confers some, albeit short-lived, incremental pro-
tection against malaria infection relative to LLINs alone; 
and, (2) replacing pyrethroids with an alternative insec-
ticide class, in this case a long-lasting CS formulation 
of the organophosphate PM, as the active ingredient for 
supplementary IRS confers considerably enhanced pro-
tection, relative to IRS with pyrethroids. Supplementing 
LLINs with IRS using non-pyrethroids therefore appears 
to be efficacious for mitigating the immediate epidemio-
logical consequences of vector population resistance to 
pyrethroids, and the observed impact on An. funestus 
densities suggest it may also be a valuable option for 
managing such resistance traits, ideally by using mosa-
ics, rotations or combinations of complementary active 
ingredients [28]. Of course the primary limitation to the 
realization of such insecticide resistance management 
and mitigation plans in practice are: (1) the availability of 
more efficacious, affordable and diverse insecticide for-
mulations [75]; (2) increased financing for malaria vec-
tor control generally [76]; and, (3) more cost-effective 
methods for targeting insecticides to vector populations 
so that both the biological resource coverage [77, 78] 
and mortality rates arising from exposure to their active 
ingredients are maximized [79–83].
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